GlassScriptPhysician profile
Ronald W Helms
NPI 1871579268
$5,335.53
in general payments reported to CMS, 2019-2025
37 companies · $651 in 2025
The $651 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $294 · 2021: $724 · 2022: $1,214 · 2023: $1,146 · 2024: $993 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,770 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,769.87 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,286.51 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,093.17 | 2021-2024 | |
| Pfizer INC. | $785.87 | 2019-2025 | |
| Glaxosmithkline, LLC. | $352.44 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $235.13 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $202.89 | 2020-2025 | Airsupra, Breztri |
| Amgen INC. | $200.91 | 2022-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $152.58 | 2021-2025 | Mounjaro, Zepbound |
| Corium, LLC | $96.47 | 2023-2024 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.93 | 2021-2025 | Jardiance |
| Ardelyx, INC. | $68.80 | 2024 | Ibsrela |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.50 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $54.44 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $51.83 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.85 | 2019-2020 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Helms listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.